Janssen v. Sun Pharma: Invega Sustenna® Consent Judgment in 173 Days
Janssen Pharmaceuticals filed suit against Sun Pharmaceutical Industries in the District of New Jersey, asserting US Patent No. 9,439,906 covering Invega Sustenna® (paliperidone palmitate injectable). The case resolved in just 173 days via a consent judgment under which Sun admitted validity and enforceability of the licensed patent and accepted a permanent injunction against launching its ANDA product prior to patent expiry.
ANDA Showdown Over Paliperidone Palmitate Ends in Agreed Injunction
Janssen Pharmaceuticals, Inc. filed this Hatch-Waxman infringement action on 9 July 2025 in the U.S. District Court for the District of New Jersey, a jurisdiction with deep familiarity in pharmaceutical patent disputes. The suit targeted Sun Pharmaceutical Industries, Inc.’s Abbreviated New Drug Application No. 217818, which sought FDA approval for a generic version of Invega Sustenna® — Janssen’s long-acting injectable formulation of paliperidone palmitate used in the treatment of schizophrenia. The single patent in suit, US9,439,906, was identified as the ‘Licensed Patent’ in the resulting consent judgment.
The action closed on 29 December 2025 via a consent judgment — a negotiated court order that carries the legal force of a final judgment. Crucially, Sun admitted, solely for settlement purposes, that the claims of US9,439,906 are valid and enforceable, and that commercialising its ANDA product in the United States prior to patent expiry would infringe those claims. Sun and all affiliates, successors, and assigns are permanently enjoined from making, using, selling, offering to sell, importing, or distributing the Sun Product unless specifically authorised by Janssen. All claims and counterclaims were dismissed with prejudice and without costs to either party.
Resolution in 173 days is notably swift for a Hatch-Waxman case, which typically involves years of litigation before trial or settlement. This timeline is consistent with parties reaching early alignment on the commercial terms of a licensed entry date — a common but publicly undisclosed element of pharma patent settlements. The public record does not reveal any agreed-upon authorised generic arrangement or future launch date for the Sun Product; those terms, if any exist, would be governed by a separate licence agreement not filed with the court.
Filing to Consent Judgment in 173 days
173 days — faster than the median Hatch-Waxman district court lifecycle, suggesting early commercial alignment
Consent judgment entered: what the agreed injunction means for both parties
Consent judgment is not a settlement in name only — it is a court order
A consent judgment differs from a private settlement agreement: it is entered by the court and is judicially enforceable. Sun’s admissions — that the Licensed Patent is valid, enforceable, and would be infringed — are binding for purposes of this action. The court retains jurisdiction to enforce compliance, meaning Janssen can return to court for contempt or injunctive relief if Sun or any affiliate breaches the injunction without further litigation over validity.
Dismissed with prejudiceJanssen secures hard injunction and formal validity admission from Sun
For Janssen, the consent judgment delivers the core objective of Hatch-Waxman litigation: blocking generic entry until patent expiry. The injunction covers Sun and all affiliates, successors, and assigns, limiting structural workarounds. The formal admission of validity — even qualified as being ‘solely for purposes of settling’ — reinforces the patent’s commercial standing and may marginally raise the bar for future challengers assessing Sun’s prior litigation posture against this patent.
Injunction securedSun retains ANDA but cannot launch without Janssen’s authorisation
Sun’s ANDA No. 217818 remains on file with the FDA and is not invalidated by this judgment; Sun retains the regulatory approval pathway. However, commercialisation in the United States is blocked pending expiry of US9,439,906 unless Janssen grants specific authorisation — suggesting the parties may have agreed to a future licensed entry date in a separate, non-public agreement. Sun’s admission of infringement forecloses re-litigation of those specific claims in this jurisdiction on these facts.
Launch blockedSwift resolution signals Janssen’s grip on the paliperidone palmitate market
Invega Sustenna® has been a multi-billion dollar franchise for Janssen. A 173-day resolution — well before any substantive patent validity briefing — is consistent with a commercial agreement that preserves Janssen’s exclusivity window while giving Sun a defined future entry date. Other ANDA filers against this patent should treat this consent judgment as a data point: Janssen has demonstrated willingness and capability to litigate rapidly and extract formal validity admissions, raising the cost calculus for any challenger considering a contested path.
Market exclusivity preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Janssen Pharmaceuticals, Inc. | Company | Pharmaceutical innovator — holder of US9439906B2 covering Invega Sustenna®Search in Eureka ↗ |
| Defendant | Sun Pharmaceutical Industries, Inc. | Company | Generic pharmaceutical manufacturer seeking FDA approval via ANDA No. 217818Search in Eureka ↗ |
| Plaintiff counsel | ANDREW D. COHEN | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | ARON R. FISCHER | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | BARBARA L. MULLIN | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | BRADLEY ALAN SUITERS | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | LACHLAN CAMPBELL-VERDUYN | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MATTHEW B. WEISS | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | MICHAEL P. HOGAN | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant counsel | TIMOTHY H. KRATZ | Attorney | Counsel for Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Defendant law firm | Kratz & Barry, LLP | Law Firm | Representing Sun Pharmaceutical Industries, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment’s language is carefully constructed: Sun’s admissions of validity, enforceability, and infringement are expressly qualified as being ‘solely for the purposes of settling the Action.’ This limits their formal preclusive effect in unrelated proceedings while still creating a court-enforceable injunction. The retention of jurisdiction clause is significant — it gives Janssen an expedited enforcement mechanism without the need to file a new action should Sun or an affiliate breach the injunction. The dismissal with prejudice and without costs to either party reflects a balanced commercial resolution rather than a litigated win for either side on the merits.
US9439906B2 — Paliperidone Palmitate Long-Acting Injectable Formulation
US Patent No. 9,439,906 (application No. 12/337,144) protects formulations and methods relating to paliperidone palmitate, the active moiety in Janssen’s Invega Sustenna® — a once-monthly intramuscular injectable approved for schizophrenia and schizoaffective disorder. The patent covers the pharmaceutical composition and dosing parameters that allow for extended-release delivery, a technically demanding achievement given paliperidone palmitate’s low aqueous solubility and the need for stable nanosuspension formulation.
From a competitive intelligence standpoint, US9,439,906 is a commercially critical asset in Janssen’s Invega franchise — a product line generating billions in annual revenue. Its claim scope over the injectable formulation, rather than merely the active compound, makes design-around difficult without fundamentally altering the drug product in ways that would require new clinical development. For generic manufacturers, this patent represents one of the primary barriers to ANDA-based entry, and Sun’s formal admission of infringement confirms its claim scope extends squarely to formulations following the reference listed drug’s composition.
Should you run an FTO analysis against US9439906B2?
Any organisation developing, formulating, or seeking regulatory approval for a paliperidone palmitate injectable — whether as a generic, biosimilar-adjacent product, or reformulation — should treat US9,439,906 as a live enforcement risk. This consent judgment confirms that Janssen will act swiftly against ANDA filers and is capable of extracting formal validity admissions before generic challengers can build a contested invalidity record. R&D teams exploring alternative dosing regimens, particle size ranges, or excipient combinations should run a thorough claim-by-claim FTO before committing to clinical or regulatory investment.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map product specifications against the full claim set of US9,439,906, identify dependent claims that may constrain design-around options, and surface related family members or continuation applications that could extend Janssen’s enforcement reach. Eureka can also identify prior art landscapes relevant to any IPR petition strategy, helping teams assess the realistic cost and probability of a contested invalidity challenge before choosing a litigation path.
Run a freedom-to-operate analysis on US9439906B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman Cases Involving Long-Acting Injectable Patents
Explore comparable ANDA infringement actions involving long-acting injectable antipsychotic formulations litigated in the District of New Jersey.
What this case signals for the paliperidone palmitate IP landscape
This consent judgment reinforces Janssen’s enforcement posture on Invega Sustenna® and sets a precedent for how future ANDA challengers may be managed.
Rapid consent judgments are a Hatch-Waxman enforcement signal, not a weakness
A 173-day resolution with a formal validity admission suggests Janssen had strong leverage from filing. Patent holders with well-documented claim scope and a history of successful enforcement can often extract consent judgments before generic challengers invest heavily in IPR or validity discovery. Monitoring the pace of resolution is as analytically important as the outcome itself.
The injunction’s affiliate clause significantly limits Sun’s structural options
The consent judgment’s definition of ‘Affiliate’ — covering entities under more than 50% common control or with directorial influence — closes the common workaround of routing a generic launch through a nominally separate subsidiary. IP teams assessing generic risk from Sun Pharma globally should factor in this broad injunction scope when modelling erosion scenarios for paliperidone palmitate.
Janssen v Sun — key questions answered
The consent judgment permanently enjoins Sun Pharmaceutical Industries and all its affiliates, successors, and assigns from making, using, selling, offering to sell, importing, or distributing the Sun Product (ANDA No. 217818) in the United States unless specifically authorised by Janssen. Sun also admitted, solely for settlement purposes, that US9,439,906 is valid, enforceable, and would be infringed by its ANDA product.
No. The consent judgment does not cancel or withdraw Sun’s ANDA No. 217818. The FDA regulatory application remains on file. However, commercialisation of the product in the United States is blocked by the injunction until US9,439,906 expires or Janssen grants specific authorisation — which may exist in a separate, non-public licence agreement not filed with the court.
The sole patent in suit is US Patent No. 9,439,906 (application No. 12/337,144), identified in the consent judgment as the ‘Licensed Patent.’ It covers formulations and methods related to paliperidone palmitate long-acting injectable, the active ingredient in Invega Sustenna®, Janssen’s once-monthly antipsychotic injection approved for schizophrenia.
The consent judgment’s admissions are expressly limited to ‘solely for the purposes of settling the Action,’ which means they do not formally preclude Sun from pursuing inter partes review at the USPTO. However, Sun’s admission of validity and enforceability, even if qualified, may create practical and reputational friction in any subsequent IPR petition, and the court’s retained jurisdiction could be invoked by Janssen if an IPR were viewed as a breach of the settlement’s spirit.
The case resolved in 173 days — significantly faster than median Hatch-Waxman litigation timelines, which often extend two to four years. This pace is consistent with parties having reached early alignment on commercial terms, typically a negotiated authorised generic launch date in a separate licence agreement. Janssen’s strong enforcement posture, the unambiguous claim scope of US9,439,906, and Sun’s apparent assessment of litigation risk likely contributed to early resolution without substantive validity briefing.
PatSnap Eureka searches patents and litigation data to answer instantly.